$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

Alumis Inc. Common Stock (ALMS)ALMS

Alumis Inc. Common Stock

$9.64

Delayed price

PASS

BUY Advisory
Profitable SELL
Loss-Inducing SELL

Profit
Loss
PASS (Skip invest)*

Time period over

ALL
YEAR
MONTH
WEEK

Time period over

Upturn Advisory Summary

11/20/2024: ALMS (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance

Type: Stock	Upturn Star Rating	Today’s Advisory: PASS
Historic Profit: 0%	Upturn Advisory Performance 1	Avg. Invested days: 0
Profits based on simulation	Stock Returns Performance 1	Last Close 11/20/2024

Type: Stock	Today’s Advisory: PASS
Historic Profit: 0%	Avg. Invested days: 0
Upturn Star Rating	Stock Returns Performance 1
Profits based on simulation Last Close 11/20/2024	Upturn Advisory Performance 1

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 630.53M USD
Price to earnings Ratio -	1Y Target Price 32.33
Dividends yield (FY) -	Basic EPS (TTM) -3.48
Volume (30-day avg) 89079	Beta -
52 Weeks Range 8.22 - 16.00	Updated Date 11/14/2024

Company Size Small-Cap Stock	Market Capitalization 630.53M USD	Price to earnings Ratio -	1Y Target Price 32.33
Dividends yield (FY) -	Basic EPS (TTM) -3.48	Volume (30-day avg) 89079	Beta -
52 Weeks Range 8.22 - 16.00	Updated Date 11/14/2024

Earnings Date

Report Date -	When -
Estimate -	Actual -

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -

Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -

Return on Equity (TTM) -

Valuation

Trailing PE -	Forward PE -
Enterprise Value 452576269	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -
Shares Outstanding 47218400	Shares Floating 14737855
Percent Insiders 1.27	Percent Institutions 71.3

Trailing PE -	Forward PE -	Enterprise Value 452576269	Price to Sales(TTM) -
Enterprise Value to Revenue -	Enterprise Value to EBITDA -	Shares Outstanding 47218400	Shares Floating 14737855
Percent Insiders 1.27	Percent Institutions 71.3

Analyst Ratings

Rating 4.67	Target Price 32.33	Buy 2
Strong Buy 4	Hold -	Sell -
Strong Sell -

Rating 4.67	Target Price 32.33	Buy 2	Strong Buy 4
Hold -	Sell -	Strong Sell -

About Alumis Inc. Common Stock

Exchange	NASDAQ	Headquaters	South San Francisco, CA, United States
IPO Launch date	2024-06-28	President, CEO & Chairman	Mr. Martin Babler Ph.D.
Sector	Healthcare	Website	https://www.alumis.com
Industry	Biotechnology	Full time employees	107
Headquaters	South San Francisco, CA, United States
President, CEO & Chairman	Mr. Martin Babler Ph.D.
Website	https://www.alumis.com
Website	https://www.alumis.com
Full time employees	107

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.